Fulltext

Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients

Manuel, Oriol

In: Current Infectious Disease Reports, 2013, vol. 15, no. 6, p. 491-496

Add to personal list
    Title
    • Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients
    Author
    • Manuel, Oriol. Infectious Diseases Service and Transplantation Center, University Hospital (CHUV) and University of Lausanne, MP14-316. CHUV, 1011, Lausanne, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Current Infectious Disease Reports, 2013, vol. 15, no. 6, p. 491-496. Springer US; http://www.springer-ny.com
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:320233
    Summary
    Novel strategies are needed to further reduce the burden of cytomegalovirus (CMV) disease in solid-organ transplant (SOT) recipients. Measurement of the specific cell-mediated immunity against CMV can identify the actual risk for the development of CMV disease in a given patient. Thus, immune monitoring is an attractive strategy for individualizing the management of CMV after transplantation. A growing number of observational studies on immune monitoring for CMV have been published over recent years, although there is a lack of data coming from interventional trials. In high-risk patients, measurement of CMV-specific T-cell responses appropriately stratifies the risk of CMV disease after discontinuation of antiviral prophylaxis. Immune monitoring may also help to identify patients followed by the preemptive approach at low risk for progression to CMV disease. Pretransplant assessment of cell-mediated immunity in seropositive patients may predict the development of posttransplant CMV infection. Overall, these studies indicate that the use of cell-mediated immunity assays has the potential to improve the management of CMV disease in SOT recipients